Understanding different liver diseases, their progression, and how they affect transplant eligibility
Liver failure can be caused by many conditions including cirrhosis (from alcohol, hepatitis, or fatty liver disease), acute liver failure (from viruses, drugs, or toxins), genetic conditions, autoimmune diseases, or bile duct diseases. The cause affects treatment options and transplant evaluation.
Cirrhosis is scarring of the liver caused by long-term damage. It can result from hepatitis B or C, alcohol-related liver disease, non-alcoholic fatty liver disease (NAFLD/NASH), autoimmune hepatitis, or genetic conditions. Cirrhosis can lead to liver failure and may require transplant.
NAFLD is buildup of fat in the liver not caused by alcohol. It ranges from simple fat accumulation (steatosis) to more severe non-alcoholic steatohepatitis (NASH), which can cause inflammation and liver damage. NASH is now a leading cause of cirrhosis and liver transplant.
Alcoholic liver disease ranges from fatty liver (reversible with abstinence) to alcoholic hepatitis and cirrhosis. To be considered for transplant, most centers require documented abstinence (typically 6 months) and participation in recovery programs.
Hepatitis is inflammation of the liver, often caused by viruses (hepatitis A, B, C), alcohol, or autoimmune conditions. Chronic hepatitis B or C can lead to cirrhosis and liver cancer. Viral hepatitis is a common cause of liver transplant worldwide.
Yes! Direct-acting antiviral (DAA) medications can cure hepatitis C with over 95% success rates. Many patients are cured before needing transplant, while others may still require transplant for advanced cirrhosis. Cured patients can receive transplants and the virus rarely recurs in the new liver.
HCC is the most common type of primary liver cancer, usually occurring in damaged livers from cirrhosis or hepatitis. Patients with early-stage HCC may qualify for liver transplant under specific criteria (Milan criteria). HCC often qualifies for MELD exceptions to increase transplant priority.
PBC is an autoimmune disease where the immune system attacks bile ducts, causing bile buildup and liver damage. It progresses slowly and can lead to cirrhosis. PBC is more common in women and can be treated with ursodiol to slow progression.
PSC is a disease that causes inflammation and scarring of bile ducts, leading to bile buildup and liver damage. PSC often occurs with inflammatory bowel disease (ulcerative colitis). There's no cure, but transplant can be life-saving. PSC can recur in the transplanted liver.
Autoimmune hepatitis occurs when the immune system attacks liver cells, causing inflammation and damage. It can occur at any age and may respond to immunosuppressive medications. Advanced cases may require transplant. It's distinct from viral hepatitis.
Genetic liver diseases include hemochromatosis (iron overload), Wilson's disease (copper overload), alpha-1 antitrypsin deficiency, and familial amyloidosis. These inherited conditions can cause progressive liver damage and may require transplant. Family screening may be recommended.
Acute liver failure is rapid liver deterioration occurring over days or weeks, often in people without pre-existing liver disease. Causes include drug overdoses (especially acetaminophen), viruses, or autoimmune conditions. It can be life-threatening and may require emergency transplant evaluation.
Early-stage liver damage (fibrosis) can sometimes be reversed with treatment, lifestyle changes, and managing the underlying cause. Advanced cirrhosis is generally considered irreversible, but management can prevent further damage. Transplant is the treatment for end-stage liver disease.
Liver cancer staging helps determine treatment options. The BCLC system stages HCC from early (Stage 0/A) to advanced (Stage C/D). Early-stage HCC may qualify for transplant under Milan criteria (single tumor ≤5cm or up to 3 tumors ≤3cm). Staging affects transplant eligibility.
Yes, patients with HCC meeting specific criteria can receive MELD exception points that boost their priority. These exceptions need to be renewed and can be denied if criteria are no longer met. HCC patients often receive transplants at lower MELD scores than non-HCC patients.